Aptevo Announces Duration Of Remission Data From Phase 1b Expansion Trial Evaluating The Bispecific APVO436 For AML
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics has announced the duration of remission data from its Phase 1b expansion trial evaluating the bispecific APVO436 for Acute Myeloid Leukemia (AML). The company plans to administer APVO436 in combination with the emerging standard of care in Phase 2 trials for relapsed/refractory and frontline settings. This new data adds to the growing body of clinical evidence supporting APVO436's clinical potential.
July 18, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo's announcement of positive data from its Phase 1b trial of APVO436 for AML and plans for Phase 2 trials could potentially boost investor confidence and positively impact the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. The announcement of plans for Phase 2 trials also indicates progress in the development of APVO436, which could further boost investor sentiment.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100